Skip to main content
SpringerLink
Log in

NEUROMUSCULAR DISEASE

Long-term benefits of nusinersen in later-onset spinal muscular atrophy

  • Research Highlight
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 17 May 2019

    In the original version of this article, the abbreviation CMAP was misspelt as CAMP. The spelling has been corrected in the HTML and PDF versions of the article.

References

Original article

Further reading

  • Groen, E. J. et al. Advances in therapy for spinal muscular atrophy: promises and challenges. Nat. Rev. Neurol. 14, 214–224 (2018)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Neurology http://www.nature.com/nrneurol/

    Ian Fyfe

Authors
  1. Ian Fyfe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian Fyfe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fyfe, I. Long-term benefits of nusinersen in later-onset spinal muscular atrophy. Nat Rev Neurol 15, 368–369 (2019). https://doi.org/10.1038/s41582-019-0202-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0202-4

  • Springer Nature Limited

Search

Navigation